ONCO TEAM DIAGNOSTIC

ONCO TEAM SPECIALISTS

The team at ONCO TEAM has 23 specialists:

o 11 general pathology seniors:

- 8 PhD (1 PhD on lung tumors pathology)

o 3 general pathology specialists;o 3 general pathology specialists;

o 2 dermopathology seniors;

o 5 biologists:

- 1 PhD in molecular biology;

- 2 PhD students;

o 5 technicians (laboratory medical assistants)

ONCO TEAM LABORATORY EQUIPMENT

ONCO TEAM pathology lab is 95% automated with latest generation equipment purchased from the following companies: THERMO, LEICA, VENTANA, ROCHE and ABBOTT MOLECULAR:

- Automated line equipment from THERMO (cryostat, tissue processor, embedding station, microtome, slide steiner, coverslipper) and from station, microtome, slide steiner, coverslipper) and from LEICA (tissue processor, embedding station, microtome, slide steiner)

- 3 immnohistochemistry automated stations:

- Benchmark Ventana ULTRA;

- Benchmark Ventana XT;

- BOND III- Leica.

- ThermoBrite Hybridisation Station – Abbott Molecular

Tissue processor Excelsior (Thermo) Tissue embedding stations(Leica and Thermo)Work Station (Thermo)

Slide stainer (Gemini) Microtome

ClearVue Coverslipper

IMMUNOHISTICHEMISTRY

Benchmark Ventana ULTRABenchmark Ventana XT

Benchmark Special Stains system

BOND III Leica

IMMUNOHISTICHEMISTRY

ThermoBrite hybridization

MICROSCOPY ROOM

KEY INDICATORS

Increase in the number of patients

Diversification and modernization of medical services

Increase of the investment in the laboratory equipmentequipment

Innovation

INCREASE IN THE NUMBER OF PATIENTS

10000

12000

14000

9249

12382

Evolution of the number of patients

0

2000

4000

6000

8000

10000

2385

48056470

9249

number of patients annually

2013 (8 months) 2014 2015 2016 2017 (10 months)

DIVERSIFICATION AND MODERNIZATION OF MEDICAL

SERVICES

2013

Histopathology and manual IHC;

Chromogenic in situ hybridization (CISH) for HER2neu;

3 technicians and 4 pathologists;

2014

40% of the IHC comprised automated techniques;

Introducing fluorescence in situ hybridization (FISH) technique in soft tissue sarcomas (STS) and HER2neu;

Introducing molecular biology techniques (KRAS and NRAS –RFLP; EGFR – PCR revers hybridization on strips);

DIVERSIFICATION AND MODERNIZATION OF MEDICAL

SERVICES

2015

Increment of sample processing quality by the acquisition of a tissue processor (Excelsior AS) and Gemini AS Slide Stainer;

60% of the IHC comprised automated techniques (including ALK/ D5F3 clone for lung adenocarcinoma).

2016

80% of the IHC comprised automated techniques with two Ventanaplatforms (XT and Ultra) (including PDL1/SP263 clone for lung adenocarcinoma and other malignancies).

For molecular biology the acquisition of Cobas Z 480 PCR platform

Introducing molecular biology techniques (KRAS, NRAS, EGFR, BRAF – Real Time PCR) for paraffin embedded tissue

DIVERSIFICATION AND MODERNIZATION OF MEDICAL

SERVICES

2017

90% of the IHC comprised automated techniques - two Ventana platforms (XT and Ultra) and Bond III platform;

For molecular biology the increment of test types on Cobas Z 480 PCR platform, by introducing the test on circulatory tumor cells DNA;

16 pathologists, 5 biologists, 5 technicians.

QUALITY ASSESSMENT

Our company has a constant interest in increasing the quality.

We have multiple yearly contracts with LabqualityFinland (3x general histopathology-interpretation, 2x special stains, 3 x IHC, each of 5 antibodies/pathology)special stains, 3 x IHC, each of 5 antibodies/pathology)

We also required IHC and molecular biology controls from the European Society of Pathology

LUNG - ESP Lung External Quality Assessment Scheme

COLON ESP External Quality Assessment Scheme

QUALITY ASSESSMENT

Oncoteam is accredited for:

ISO 15189 Standards: For Medical ISO 15189 Standards: For Medical and Clinical Laboratories

ISO 9001 - Quality management

INNOVATION

The pathologists and some of the biologists from ONCO TEAM have years of experience in the research field (from the period they activated in Victor Babes National Institute and the University of Bucharest) 23 national research projects, 1 POSCCE and 1 POSDRUnational research projects, 1 POSCCE and 1 POSDRU

Currently Onco Team is involved in the project “Liquid biopsy technology development for prognostics and therapy modulation in malignant epithelial cancers” PN-III-P (national project) 2-2.1-PTE-2016-0149

“Liquid biopsy technology development for prognostics and therapy modulation in prognostics and therapy modulation in malignant epithelial cancers” (poster)PN-III-P (national project) 2-2.1-PTE-2016-0149la al 29-lea Congres European de Patologie2-6 Septembrie 2017, Amsterdam Olanda

THE DYNAMIC OF BUSINESS INDICATORS

2500000

3000000

3500000

Evolution of key indicators

-500000

0

500000

1000000

1500000

2000000

2013 2014 2015 2016

Profit

Turnover

investment

Thank you for your attention!your attention!